닫기

Ex) Article Title, Author, Keywords

Review Article

Journal of Digestive Cancer Research 2018; 6(1): 16-24

Published online June 30, 2018

© Korean Society of Gastrointestinal Cancer

진행성 위암의 항암 약물 요법에 대하여

Oncological Treatment of Advanced Gastric Cancer

문희석, 정현용
Hee Seok Moon, Hyun Yong Jeong


충남대학교 의과대학 내과학교실, 소화기내과
Division of Gastroenterology, Department of Internal Medicine, Chungnam National University Hospital, Daejeon, Korea

Abstract

Gastric cancer is not a single, uniform disease, but rather heterogeneous in nature. It is generally not possible to cure patients with inoperable advanced or metastatic stomach cancer. In the absence of chemotherapy, the median survival time is 3 to 6 months. Therefore, several studies have confirmed the superiority of chemotherapy to the best supportive treatment, in terms of improving the quality of life and prolonging life. Various chemotherapies have been used in the past to treat advanced gastric cancer. Recently, various target therapies and immunotherapy have been introduced. However, compared to other malignancies, the quality of life and life expectancy remain relatively poor in patients with gastric cancer. We expect to overcome these difficulties in the future, with better elucidation of the molecular biology of gastric cancer.

KeywordsStomach cancer Chemotherapy Target therapy Immunotherapy

Article

Review Article

Journal of Digestive Cancer Research 2018; 6(1): 16-24

Published online June 30, 2018

Copyright © Korean Society of Gastrointestinal Cancer Research.

진행성 위암의 항암 약물 요법에 대하여

문희석, 정현용

충남대학교 의과대학 내과학교실, 소화기내과

Oncological Treatment of Advanced Gastric Cancer

Hee Seok Moon, Hyun Yong Jeong

Division of Gastroenterology, Department of Internal Medicine, Chungnam National University Hospital, Daejeon, Korea

Abstract

Gastric cancer is not a single, uniform disease, but rather heterogeneous in nature. It is generally not possible to cure patients with inoperable advanced or metastatic stomach cancer. In the absence of chemotherapy, the median survival time is 3 to 6 months. Therefore, several studies have confirmed the superiority of chemotherapy to the best supportive treatment, in terms of improving the quality of life and prolonging life. Various chemotherapies have been used in the past to treat advanced gastric cancer. Recently, various target therapies and immunotherapy have been introduced. However, compared to other malignancies, the quality of life and life expectancy remain relatively poor in patients with gastric cancer. We expect to overcome these difficulties in the future, with better elucidation of the molecular biology of gastric cancer.

Keywords: Stomach cancer, Chemotherapy, Target therapy, Immunotherapy

Journal Info

JDCR
Vol.12 No.3
December 20, 2024
eISSN : 2950-9505
pISSN : 2950-9394
Frequency: Triannual

open access

Article Tools

Stats or Metrics

Share this article on

  • line

Journal of Digestive Cancer Research

eISSN 2950-9505
pISSN 2950-9394

  • 2021
  • 2022
  • 2023
  • 2024
  • 2025